Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies,CNS Neuroscience & Therapeutics

当前位置： X-MOL 学术 › CNS Neurosci. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies
CNS Neuroscience & Therapeutics ( IF 4.8 ) Pub Date : 2020-09-08 , DOI: 10.1111/cns.13458
Liao Weiping ₁ , Zhou Dong ₂ , Hong Zhen ₃ , Anna Patten ₄ , Amitabh Dash ₅ , Manoj Malhotra ₆

Affiliation

This post hoc analysis assessed the efficacy and safety/tolerability of adjunctive perampanel in patients from China (aged ≥12 years) with focal seizures (FS), with/without focal to bilateral tonic‐clonic seizures (FBTCS), or generalized tonic‐clonic seizures (GTCS).

更新日期：2020-09-08

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11